De moine et al. [72] reported that N-acetylcysteine could be safely administered in cirrhosis patients with alcoholic hepatitis, with an improvement in some biological parameters (including significant decreases in aspartate transaminase, alkaline phosphatase, and prothrombin time). The gene discussed is F2; the disease is Cirrhosis.